Evidence map›Paper›PMID 41334788›Full record

ReviewAdvanced healthcare materials2026

Microneedle Technology in Psoriasis Management: Mechanistic Insights, Technological Innovation, Clinical Progress, and Challenges.

Fatma Moawad, Yasmine Ruel, Roxane Pouliot, Davide Brambilla

Abstract readReview
In one paragraph

Review in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fatma MoawadFaculté de Pharmacie, Université De Montréal, Montréal, Québec, Canada.ORCID https://orcid.org/0000-0002-1451-9730
Yasmine RuelFaculté de Pharmacie, Université Laval, Québec, Québec, Canada.
Roxane PouliotFaculté de Pharmacie, Université Laval, Québec, Québec, Canada.
Davide BrambillaFaculté de Pharmacie, Université De Montréal, Montréal, Québec, Canada.

Funding

Canadian Generic Pharmaceutical Association and Biosimilars Canada, and the Canada Institute of Health Research PJT.165822Faculté de pharmacie at the Université de Montréal, the Fonds de Recherche du Québec-Nature et technologies FRQNT#331629Fonds de Recherche du Québec-Santé, the Natural Sciences and Engineering Research Council of Canada (Discovery program RGPIN-2018-05076
6 · The paper itself

Abstract

Psoriasis is a chronic dermatological disorder that affects millions worldwide, impairing their quality of life. Current therapeutic modalities, topical, conventional systemic, and biologic, present significant limitations. Topical agents often exhibit inadequate penetration through psoriatic plaques, yielding suboptimal outcomes. Systemic therapies and biologics, while more potent, carry risks of serious adverse effects, necessitating rigorous monitoring and limiting their long-term utility. Despite these challenges, optimizing existing treatment strategies remains valuable. Microneedle technology has emerged as a minimally invasive, skin-targeted approach offering enhanced drug delivery, localization, and patient compliance. This review provides an in-depth analysis of microneedle-based strategies tailored for psoriasis, beginning with current therapy shortcomings, unmet needs in psoriasis management, and principles of microneedle technology. We then critically evaluate microneedle integration across diverse therapeutic domains, from topical formulations to biologics, off-label therapies, and phytomedicines, alongside emerging therapeutic innovations. Additionally, we highlight microneedle potential in psoriasis diagnosis and monitoring, underscoring its versatility and growing significance in psoriasis management. The review wraps up by discussing key limitations of microneedle technology, outlining strategic pathways for clinical translation, and offering a comparative perspective of various microneedle types in psoriasis care. Altogether, microneedles represent a paradigm shift toward precision dermatology, with the potential to revolutionize psoriasis management.

Indexed as

Drug Delivery SystemsNeedlesPsoriasisAnimalsHumansclinical translationdiagnosislimitationsmicroneedlespsoriasistherapytransdermal delivery

Identifiers

PMID41334788
PMCPMC12988575

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.